» Articles » PMID: 34067440

MiR155 Deficiency Reduces Myofibroblast Density but Fails to Improve Cardiac Function After Myocardial Infarction in Dyslipidemic Mouse Model

Overview
Journal Int J Mol Sci
Publisher MDPI
Date 2021 Jun 2
PMID 34067440
Citations 6
Authors
Affiliations
Soon will be listed here.
Abstract

Myocardial infarction remains the most common cause of heart failure with adverse remodeling. MicroRNA (miR)155 is upregulated following myocardial infarction and represents a relevant regulatory factor for cardiac remodeling by engagement in cardiac inflammation, fibrosis and cardiomyocyte hypertrophy. Here, we investigated the role of miR155 in cardiac remodeling and dysfunction following myocardial infarction in a dyslipidemic mouse model. Myocardial infarction was induced in dyslipidemic apolipoprotein E-deficient (ApoE) mice with and without additional miR155 knockout by ligation of the LAD. Four weeks later, echocardiography was performed to assess left ventricular (LV) dimensions and function, and mice were subsequently sacrificed for histological analysis. Echocardiography revealed no difference in LV ejection fractions, LV mass and LV volumes between ApoE and ApoE/miR155 mice. Histology confirmed comparable infarction size and unaltered neoangiogenesis in the myocardial scar. Notably, myofibroblast density was significantly decreased in ApoE/miR155 mice compared to the control, but no difference was observed for total collagen deposition. Our findings reveal that genetic depletion of miR155 in a dyslipidemic mouse model of myocardial infarction does not reduce infarction size and consecutive heart failure but does decrease myofibroblast density in the post-ischemic scar.

Citing Articles

Noncoding RNAs and Cardiac Fibrosis.

Wu C, Bao S, Li R, Sun H, Peng Y Rev Cardiovasc Med. 2024; 24(2):63.

PMID: 39077397 PMC: 11273127. DOI: 10.31083/j.rcm2402063.


The Role of ncRNAs in Cardiac Infarction and Regeneration.

Cano-Carrillo S, Lozano-Velasco E, Castillo-Casas J, Sanchez-Fernandez C, Franco D J Cardiovasc Dev Dis. 2023; 10(3).

PMID: 36975887 PMC: 10052289. DOI: 10.3390/jcdd10030123.


Novel Biomarkers of Atherosclerotic Vascular Disease-Latest Insights in the Research Field.

Adam C, Salaru D, Prisacariu C, Marcu D, Sascau R, Statescu C Int J Mol Sci. 2022; 23(9).

PMID: 35563387 PMC: 9103799. DOI: 10.3390/ijms23094998.


MiR-410-3p facilitates Angiotensin II-induced cardiac hypertrophy by targeting Smad7.

Jia G, Liang C, Li W, Dai H Bioengineered. 2021; 13(1):119-127.

PMID: 34951337 PMC: 8805929. DOI: 10.1080/21655979.2021.2009968.


Heart function assessment during aging in apolipoprotein E knock-out mice.

Liehn E, Lupan A, Diaconu R, Ioana M, Streata I, Manole C Discoveries (Craiova). 2021; 9(3):e136.

PMID: 34816004 PMC: 8605688. DOI: 10.15190/d.2021.15.


References
1.
Wei Y, Yan X, Yan L, Hu F, Ma W, Wang Y . Inhibition of microRNA‑155 ameliorates cardiac fibrosis in the process of angiotensin II‑induced cardiac remodeling. Mol Med Rep. 2017; 16(5):7287-7296. PMC: 5865857. DOI: 10.3892/mmr.2017.7584. View

2.
Cao R, Li Q, Miao Y, Zhang Y, Yuan W, Fan L . The Emerging Role of MicroRNA-155 in Cardiovascular Diseases. Biomed Res Int. 2016; 2016:9869208. PMC: 5149600. DOI: 10.1155/2016/9869208. View

3.
Guo J, Liu H, Sun C, Yan X, Hu J, Yu J . MicroRNA-155 Promotes Myocardial Infarction-Induced Apoptosis by Targeting RNA-Binding Protein QKI. Oxid Med Cell Longev. 2019; 2019:4579806. PMC: 6525929. DOI: 10.1155/2019/4579806. View

4.
Kazimierczyk E, Eljaszewicz A, Zembko P, Tarasiuk E, Rusak M, Kulczynska-Przybik A . The relationships among monocyte subsets, miRNAs and inflammatory cytokines in patients with acute myocardial infarction. Pharmacol Rep. 2018; 71(1):73-81. DOI: 10.1016/j.pharep.2018.09.007. View

5.
Scarlatescu A, Micheu M, Popa-Fotea N, Dorobantu M . MicroRNAs in Acute ST Elevation Myocardial Infarction-A New Tool for Diagnosis and Prognosis: Therapeutic Implications. Int J Mol Sci. 2021; 22(9). PMC: 8124280. DOI: 10.3390/ijms22094799. View